An FDA Advisory Committee has voted unanimously in support of the use of Novartis' (NVS)...
Wednesday, November 7, 2012, 5:06 PM ETAn FDA Advisory Committee has voted unanimously in support of the use of Novartis' (NVS) Signifor, a treatment for patients with Cushing's disease who require medical therapeutic intervention. The drug is the first of its kind for this potentially debilitating endocrine disorder caused by a pituitary tumor that triggers excess cortisol. Phase III clinical trials showed patients who used Signifor experienced a rapid and sustained decrease in mean cortisol levels.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles